Monocyte-derived dendritic cell subsets
OwnerJuha Punnonen, Chia-Chun J. Changinventors
Life of this patent
Estimating the term…
Abstract
A novel subset of monocyte-derived dendritic cells are provided. Methods for producing these monocyte-derived dendritic cells and compositions comprising the dendritic cells of the invention are also provided. Methods for inducing an immune response to an antigen of interest using the dendritic cells of the invention are provided. Also provided are methods for therapeutically or prophylactically treating a disease in a subject suffering from the disease using the dendritic cells.
Claims69
A method of producing a differentiated antigen presenting cell (APC), the method comprising:
- culturing a population of peripheral blood or bone marrow mononuclear cells in interleukin-4 (IL-4), granulocyte macrophage colony stimulating factor (GM-CSF), and a culture medium comprising insulin, transferrin, linoleic acid, oleic acid, palmitic acid for a sufficient time to produce the differentiated antigen presenting cell.
A differentiated antigen presenting cell (APC), which differentiated APC does not express CDla cell surface marker.
A method of inducing in a subject an immune response to at least one antigen, said method comprising administering to the subject a population of CD1a− dendritic cells, said CD1a− dendritic cells presenting at least one of said at least one antigen, in an amount sufficient to induce the immune response to said at least one antigen.
A method of inducing differentiation of T cells, the method comprising:
- co-culturing a population of T cells with population of CD1a− antigen presenting cells (APC), thereby inducing or promoting differentiation of said T cells.
A composition comprising CD1a− dendritic cells.
A method of inducing or modulating an immune response in an immunocompromised subject, said method comprising administering to the subject a population of CD1a− dendritic cells in an amount sufficient to induce or modulate an immune response in the subject.
An ex vivo method of inducing in a subject a therapeutic or prophylactic immune response against at least one antigen, the method comprising:
- a) culturing a population of monocytes obtained from the subject with IL-4, GM-CSF, and a culture medium comprising Iscove's Modified Dulbecco's Medium (IMDM) supplemented with insulin, transferrin, linoleic acid, oleic acid and palmitic acid for a sufficient time to produce a population of dendritic cells comprising CD1a− dendritic cells;
- b) introducing to the population of CD1a− dendritic cells a sufficient amount of at least one antigen, or a sufficient amount of an exogenous DNA sequence operably linked to a promoter that controls expression of said DNA sequence, said DNA sequence encoding at least one or said at least one antigen, such that the presentation of the antigen on the CD1a− dendritic cells results;
- and
- c) administering the antigen-presenting CD1a− dendritic cells to the subject in an amount sufficient to induce a therapeutic or prophylactic immune response against said at least one antigen.
A method for therapeutically or prophylactically treating a disease in a subject suffering from said disease, the method comprising:
- a) culturing a population of monocytes obtained from the subject with IL-4, GM-CSF, and a culture medium comprising Iscove's Modified Dulbecco's Medium (IMDM) supplemented with insulin, transferrin, linoleic acid, oleic acid and palmitic acid for a sufficient time to produce a population of CD1a− dendritic cells;
- b) introducing to the population of CD1a− dendritic cells a sufficient amount of at least one disease-associated antigen, or a sufficient amount of an exogenous DNA sequence operably linked to a promoter that controls expression of said DNA sequence, said DNA sequence encoding at least one of said at least one disease-associated antigen, such that presentation of the disease-associated antigen on the CD1a− dendritic cells results;
- and
- c) administering a therapeutic or prophylactic amount of the CD1a− dendritic cells presenting the disease-associated antigen to the subject to treat said disease.
A method for therapeutically or prophylactically treating a disease in a subject suffering from the disease, the method comprising:
- a) culturing a population of monocytes obtained from the subject with IL-4, GM-CSF, and a culture medium comprising Iscove's Modified Dulbecco's Medium (IMDM) supplemented with insulin, transferrin, linoleic acid, oleic acid and palmitic acid for a sufficient time to produce a population of CD1a− dendritic cells;
- b) contacting the population of CD1a− dendritic cells with a population of diseased cells from a tissue or organ of the subject, thereby inducing presentation of a disease-associated antigen on the CD1a− dendritic cells;
- and
- c) administering a therapeutic or prophylactic amount of CD1a− dendritic cells presenting the disease-associated antigen to the subject to treat the disease.
A monocyte-derived dendritic cell, wherein the dendritic cell does not express a CD1a cell marker, substantially lacks EL-12 production, produced IL-1, and promotes Th0/Th2 lineage differentiation of T cells.
A monocyte-derived dendritic cell produced by culturing a population of monocyte cells in interleukin-4 (IL-4), granulocyte macrophage coloby stimulating factor (GM-CSF), and a culture medium comprising insulin, transferrin, linoleic acid, oleic acid, and palmitic acid, wherein the monocyte-derived dendritic cell has an altered cytokine profile compared to a dendritic cell produced by culturing a population of monocyte cells in IL-4, GM-CSF, and a culture medium comprising RPMI.
Dependencies are inferred from the claim text.